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Background. Cotrimoxazole preventive therapy (CPT) is recommended for all human immunodeficiency virus
(HIV)–exposed infants to avoid opportunistic infections. Cotrimoxazole has antimalarial effects and appears to re-
duce clinical malaria infections, but the impact on asymptomatic malaria infections is unknown.
Methods. We conducted an observational cohort study using data and dried blood spots (DBSs) from the
Breastfeeding, Antiretrovirals and Nutrition study to evaluate the impact of CPT on malaria infection during
peak malaria season in Lilongwe, Malawi. We compared malaria incidence 1 year before and after CPT implemen-
tation (292 and 682 CPT-unexposed and CPT-exposed infants, respectively), including only infants who remained
HIV negative by 36 weeks of age. Malaria was defined as clinical, asymptomatic (using DBSs at 12, 24, and 36 weeks),
or a composite outcome of clinical or asymptomatic. Linear and binomial regression with generalized estimating
equations were used to estimate the association between CPT and malaria. Differences in characteristics of parasi-
temias and drug resistance polymorphisms by CPT status were also assessed in the asymptomatic infections.
Results. CPTwas associated with a 70% (95% confidence interval, 53%–81%) relative reduction in the risk of asymp-
tomatic infection between 6 and 36 weeks of age. CPT appeared to provide temporary protection against clinical malaria
and more sustained protection against asymptomatic infections, with no difference in parasitemia characteristics.
Conclusions. CPT appears to reduce overall malaria infections, with more prolonged impacts on asymptomatic in-
fections. Asymptomatic infections are potentially important reservoirs for malaria transmission. Therefore, CPT prophy-
laxis may have important individual and public health benefits.
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The World Health Organization (WHO) recommends
that all human immunodeficiency virus (HIV)–exposed
infants begin cotrimoxazole preventive therapy (CPT)
between 4 and 6 weeks of age, and continue CPT
until at least 6 weeks after cessation of breastfeeding
and until HIV infection has been ruled out [1]. CPT
is used to avoid often-fatal opportunistic infections
among children born to HIV-infected women, and in
turn reduces hospital admissions. CPT use among
HIV-infected adults and children has been associated
with reductions in malaria incidence, as cotrimoxazole
has antimalarial activity [2–4]. Similarly, CPT has been
associated with reduced incidence of clinical malaria
among HIV-exposed but uninfected (HEU) infants,
with some suggestion that protective benefits may
wane over time [5–7]. As early infant HIV diagnosis
services are becoming more widely available in Africa,
and asmore efficacious drug regimens for the prevention
of mother-to-child HIV transmission are being adopted
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and extended throughout the breastfeeding period, the popula-
tion of HEU infants is growing. A better understanding of the
impact of CPT on malaria among HEU infants is needed.
To date, only clinical or symptomatic malaria has been exam-
ined in studies of CPT use and malaria incidence. However,
clinical malaria represents only a portion of all malaria infec-
tions, as many malaria infections are asymptomatic. Although
asymptomatic infections are more common in older children,
they do occur in infants. We assessed the association between
CPT and a composite outcome of clinical or asymptomatic
infection. Additionally, we evaluated the association between
CPT and both clinical and asymptomatic infections separately.
Including asymptomatic infection adds valuable information
concerning the routine use of CPT among the growing popu-
lation of HEU infants, as the role of asymptomatic parasitemia
in malaria transmission has garnered increasing attention.
Although density of parasitemia and gametocytemia af-
fects transmission efficiency [8], transmission may occur from
asymptomatic patients and patients with submicroscopic para-
sitemia [9].
In addition to assessing the impact of CPT onmalaria infection,
we also compared characteristics of the asymptomatic infections
by CPT status. Specifically, we assessed (1) parasitemia levels;
(2) complexity of individual infections, as in high-transmission
areas such as Malawi infections are often polyclonal; and (3)
frequency of single-nucleotide polymorphisms in dhfr and
dhps, the genes associated with resistance to antifolate antima-
larials. Because resistance to antifolate antimalarials is common
in Africa, understanding how CPT affects parasite characteris-




We used data and infant dried blood spot (DBS) specimens
from the Breastfeeding, Antiretrovirals, and Nutrition (BAN)
study, which has been described elsewhere [10, 11]. Beginning
in June 2006, 240 mg of cotrimoxazole was provided once daily
to all HIV-exposed infants 6 weeks after birth, or as soon as pos-
sible thereafter, and continued through 36 weeks of age due to
compliance with Malawian national guidelines and WHO rec-
ommendations. Infants reaching 36 weeks of age prior to June
2006 did not routinely receive CPT. To compare malaria inci-
dence 1 year before and after implementation of CPT, we in-
cluded HEU infants born between 22 August 2004 and 21
August 2005 (CPT unexposed, n = 292), and those born be-
tween 22 August 2006 and 21 August 2007 (CPT exposed,
n = 682). Dates were chosen to ensure that all infants were at
least 6 weeks of age (and therefore eligible for CPT in the
later time period) by the start of peak malaria season (October),
and to mitigate any confounding effects of calendar time. Infant
HIV-1 status was determined by Roche Amplicor 1.5 DNA po-
lymerase chain reaction (PCR) (Roche Molecular Systems,
Pleasanton, California) at 2, 12, 28, and 48 weeks. PCR-positive
results were confirmed by testing an additional blood specimen,
and the window of infection was narrowed with tests of infant
DBS specimens taken at 4, 6, 8, 18, 24, 32, and 36 weeks. All
mothers were advised to breastfeed exclusively for the first 24
weeks postpartum, and to wean between 24 and 28 weeks.
Only malaria events occurring during peak malaria season
(October–April) were used to increase the likelihood of detect-
ing clinical and asymptomatic parasitemias. Infants born be-
tween 22 August 2005 and 21 August 2006 were excluded to
avoid exposure misclassification while the new CPT policy
was being implemented. Infants who were diagnosed as HIV in-
fected between birth and 36 weeks of age (n = 84) or had a doc-
umented episode of clinical malaria before 6 weeks of age
(n = 8) were excluded. A total of 882 infants of the 2369 moth-
er–infant pairs enrolled in the BAN study cohort met eligibility
criteria.
Data Analyses
Malaria was defined 3 ways: (1) clinical, (2) asymptomatic, and
(3) a composite outcome of clinical and asymptomatic. Clinical
malaria was defined as having clinical symptoms of malaria
with documented microscopy-positive parasitemia between 6
and 36 weeks of age (n = 148). In addition, infants with a doc-
umented serious adverse event due to malaria were considered
as having clinical malaria even if documented microscopy-
positive parasitemia was unavailable (n = 4). To assess for
changes in the association between CPT and malaria by infant
age, clinical malaria was also categorized as occurring at 6–12,
13–24, or 25–36 weeks of age. If an infant had multiple malaria
events, only events occurring >1 week apart were counted as a
recurrent event and used in analyses.
Asymptomatic infection was determined from available DBS
specimens collected during peak malaria season. A total of 471,
517, and 564 infants were 12, 24, and 36 weeks of age, respec-
tively, during peak malaria season. Among these, DBSs were
available for 230 (49%) infants at 12 weeks of age, 235 (45%)
at 24 weeks, and 215 (38%) at 36 weeks. Infants who were miss-
ing DBSs at 12, 24, or 36 weeks did not differ from infants
who had an available DBS, with respect to characteristics out-
lined in Table 1. Missing asymptomatic infection information
was therefore considered missing completely at random. Sam-
ples testing positive for malaria parasites by 2 previously de-
scribed real-time PCR assays were considered positive [12].
Samples positive with only 1 assay were considered indetermi-
nate and not used in analyses. Asymptomatic infection was
treated as a dichotomous variable (detectable vs undetectable
parasitemia).
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We compared maternal malaria prevalence by time period to
assess for any confounding effects of malaria transmission dif-
ferences across calendar time. Malaria exposure can vary greatly
across small geographic distances [13, 14]. Maternal malaria
prevalence was therefore thought to provide a more valid
proxy of transmission differences over time, compared to ma-
laria prevalence data for the community at large. Maternal ma-
laria prevalence was calculated using clinical malaria data
among mothers with a CD4 count >500 cells/µL and therefore
not receiving routine maternal CPT.
Frequencies, means, and medians were calculated, as appro-
priate, to compare characteristics of mother–infant pairs by ex-
posure (CPT status) and outcome (malaria) category. Binomial
regression models using generalized estimating equation (GEE)
with an autoregressive correlation structure were used to esti-
mate risk ratios (RRs) for malaria by CPT status when malaria
was treated as a dichotomous variable. Linear regression with
GEE was used when asymptomatic infection was treated as a
continuous variable. Mann–Whitney test was used to assess dif-
ferences in median parasitemia level and median multiplicity of
infection (MOI) by CPT status, Fisher exact test was used to as-
sess differences in maternal malaria prevalence by time period,
and unpaired t test was used to assess differences in presence of
resistance polymorphisms.
The following parameters were assessed for potential con-
founding or effect measure modification: BAN study antiretro-
viral and nutritional randomization assignment, maternal
characteristics, infant health status information, and maternal
malaria prevalence. Parameters were decided based on expert
knowledge and use of a causal diagram to identify a minimally
sufficient adjustment set [15]. Effect measure modification was
assessed by comparing unadjusted and adjusted estimates and
95% confidence intervals (CIs) using an interaction term be-
tween CPT and the variable of interest. Covariates that pro-
duced adjusted estimates that were different enough to be
clinically or programmatically relevant were considered effect
measure modifiers. Among variables identified in the minimally
sufficient adjustment set, confounding was assessed using a
change-in-estimate approach. If the change-in-estimate of the
odds ratio was >10% (|ln(ORreduced/ORfull)| > 0.10), and the co-
variate was not an effect measure modifier, the covariate was
treated as a confounder. All data analyses were conducted
using SAS version 9.3 (SAS Institute, Cary, North Carolina).
Molecular Analysis of Asymptomatic Parasitemias
Molecular analysis was performed on all DBSs to determine
asymptomatic parasitemias. We determined the parasitemia of
each infection using real-time PCR to detect the single-copy
gene Plasmodium falciparum lactate dehydrogenase (pfldh) as
previously described [16]. Parasitemia data by microscopy for
clinical events was not recorded and no biologic specimens
were available to perform molecular analysis. Complexity of in-
fection was assessed by nested PCR amplification of merozoite
surface protein 2 (msp2) as previously described [17]. The am-
plified fragments were sized by capillary electrophoresis using
the High Sensitivity DNA1000 kit on an Agilent Tape Station
2200 (Agilent Technologies, Santa Clara, California). Bands
representing >10% of the height of the largest peak in the sam-
ple were counted. Drug resistance polymorphism frequency was
determined using a modified version of a previously described
pooled deep sequencing approach [18, 19]. This approach uses










Maternal antiretroviral 294 (33) 235 (34) 59 (33)
Infant nevirapine 297 (34) 239 (34) 58 (32)
Enhanced control 291 (33) 227 (32) 64 (35)
Nutritional randomization
No supplement 449 (51) 357 (51) 92 (51)
Received supplement 433 (49) 344 (49) 89 (49)
Mothersb
Age, y
15–25 436 (50) 355 (51) 81 (45)
26–35 404 (46) 312 (45) 92 (51)
36–45 39 (4) 33 (5) 6 (3)
Parity
0 133 (15) 109 (16) 24 (13)
≥1 748 (85) 591 (84) 57 (87)
Education
Primary school only 567 (64) 441 (63) 126 (70)
More than primary
school
314 (36) 260 (37) 54 (30)
Infantsb
Sex
Female 443 (50) 350 (50) 93 (51)
Male 439 (50) 351 (50) 88 (49)
Birth weight, kg
<2.5 66 (8) 56 (8) 10 (6)
≥2.5 814 (93) 643 (92) 171 (94)
Hemoglobin, g/dL
<13.4 54 (6) 44 (6) 10 (6)
≥13.4 828 (94) 657 (94) 171 (94)
Neutropenia, ×103 cells/µL
<1 23 (3) 18 (3) 5 (3)
≥1 859 (97) 683 (97) 176 (97)
Data are presented as No. (%).
a Malaria defined as clinical or polymerase chain reaction–positive malaria.
b Maternal age missing for 3 mother–infant pairs, parity andmaternal education
missing for 1 mother–infant pair, infant birthweight missing for 2 infants.
Percentages may not add to 100 due to rounding.
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pools created by mixing equal volumes of extracted DNA from
each sample and has been shown to create accurate allele
frequency measurements compared to Sanger sequencing of in-
dividual samples [18]. Pools for participants exposed and unex-
posed to CPT were created and amplified in duplicate for the
dhfr and dhps regions containing key sulfadoxine-pyrimeth-
amine resistance polymorphisms. The dhfr region was ampli-
fied using sequence-specific primers as previously reported
[18]. The dhps region was amplified using 800 nM primer
437-F (TGAAATGATAAATAAGGTGCTAGTGT), 800 nM
primer 613-R (GTTGTGTATTTATATTTTGATCATTC), KAPA
HiFi Fidelity Buffer (KAPA Biosystems, Boston, Massachusetts),
400 µM KAPA dNTP Mix, 1 U of KAPA HiFi HotStart DNA
Polymerase, and 5 µL of sample DNAwith the following cycling
parameters: 95°C for 3 minutes; 40 cycles of 98°C for 20 sec-
onds, 63°C for 20 seconds, and 72°C for 60 seconds; and exten-
sion at 72°C for 2 minutes with a 4°C hold. The PCR products
were then sheared as previously described [19], size selected by
E-gel (Life Technologies, Grand Island, New York) and library
prepped by the Ion Plus Fragment Library Kit (Life Techno-
logies). The indexed libraries were sequenced on a 314 chip
using an Ion Torrent PGM (Life Technologies). Read align-
ment and scoring of allele frequency were done as previously
described [18]. The following polymorphic sites were evalu-
ated: N51I, C59R, S108N, and I164L in dhfr and S436A,




Characteristics of study participants are shown in Table 1. In
addition, prevalence of clinical malaria among mothers with a
CD4 count >500 cells/µL did not significantly differ by time pe-
riod (23% in CPT-unexposed group, 19% in CPT-exposed
group; P = .4).
The primary outcome was episodes of malaria, defined as a
combination of clinical and/or asymptomatic infections. A
total of 181 (21%) infants experienced at least 1 episode of clin-
ical (n = 137) and/or asymptomatic (n = 61) infection, 11 in-
fants had 2 episodes of clinical malaria, and 2 infants had 3
episodes of clinical malaria between 6 and 36 weeks of age dur-
ing peak malaria season. Twelve infants experienced an episode
of both asymptomatic infection and clinical malaria, with 5 in-
fants experiencing both a clinical and asymptomatic infection
event within a time interval (4 at 13–24 weeks and 1 at 25–36
weeks). In all cases, the asymptomatic event occurred >4 weeks
after the clinical event and, therefore, both events were included
in analyses. In total, 67 CPT-unexposed infants (26%) and 114
CPT-exposed infants (18%) experienced at least 1 episode of
clinical malaria or asymptomatic infection.
Overall, daily infant CPT was associated with 0.65 (95% CI,
.49–.86) times the risk of having clinical or asymptomatic infec-
tion between 6 and 36 weeks of age during peak malaria season,
corresponding to a 35% (95% CI, 14%–51%) relative reduction in
malaria (Table 2). When combining all time intervals and evalu-
ating clinical malaria separately, daily CPT use was not associated
with a statistically significant decrease in the relative risk of clinical
malaria (RR, 0.81 [95% CI, .58–1.15]). However, CPT was associ-
ated with a large decrease in the relative risk of asymptomatic
infection from 12 to 36 weeks (RR, 0.30 [95% CI, .19–.47]).
Adjustment for infant birth weight and antiretroviral randomiza-
tion had little to no impact.
The relative reduction in malaria risk differed by infant’s age,
with CPT having a stronger effect on malaria risk during the
first few months of life and decreasing thereafter (Table 2).
Comparing malaria type (clinical vs asymptomatic), daily
CPT was associated with a 67% (95% CI, 18%–87%) relative re-
duction in the risk of clinical malaria between 6 and 12 weeks of
infant age, but no statistically significant relative reduction
thereafter. Daily CPT was associated with a 68%–86% relative
reduction in the risk of asymptomatic infection during peak
malaria season, compared with not receiving daily CPT. How-
ever, the relative reduction was not statistically significant at 36
weeks of age, likely due to the small number of asymptomatic
infection events at 36 weeks (n = 5).
Table 2. Association Between Cotrimoxazole Preventive Therapy
and Both Clinical Malaria and Asymptomatic Infection, by Infant
Age
Type of Infection No. of Events RR (95% CI)
Clinical or asymptomatic infection
Daily infant CPT vs no infant CPT
6–12 wk 30 0.38 (.19–.77)
13–24 wk 80 0.53 (.34–.80)
25–36 wk 98 0.96 (.63–1.48)
Overall: 6–36 wk 208 0.65 (.49–.86)
Clinical malaria only
Daily infant CPT vs no infant CPT
6–12 wk 18 0.33 (.13–.82)
13–24 wk 40 0.85 (.44–1.63)
25–36 wk 94 0.96 (.62–1.49)
Overall: 6–36 wk 152 0.81 (.58–1.15)
Asymptomatic infection only
Daily infant CPT vs no infant CPT
12 wk 12 0.26 (.09–.78)
24 wk 44 0.32 (.19–.55)
36 wk 5 0.14 (.02–1.27)
Overall: 12–36 wk 61 0.30 (.19–.47)
Abbreviations: CI, confidence interval; CPT, cotrimoxazole preventive therapy;
RR, risk ratio.
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Impact of CPT on the Characteristics of Asymptomatic Infection
All infections detected by molecular methods in this study were
P. falciparum infections. We were able to determine a parasite-
mia from all 61 available samples (CPT unexposed: 35 samples,
CPT exposed: 26 samples; geometric mean: 2.75 genome equiv-
alents/µL). When parasitemia occurred, the parasitemia levels
were similar by CPT status (mean difference, −0.20 [95% CI,
−.67 to .27]). Complexity of infection was determined for 58
of 61 (95%) samples. The use of CPT was not associated with
a decrease in the MOI, with a mean MOI of 1.7 in the treated
infants and 1.9 in the untreated infants (P = .5).
In total, 224 659 sequences spanning dhfr and dhps passed
the sequencing quality and mapping filters, with a mean num-
ber of sequences per PCR of 28 082 (range, 17 885–36 213). All
sites evaluated for known drug polymorphisms (listed in last
sentence of “Methods” section) were covered by >1000 sequenc-
ing reads. Mutant alleles were seen only at 4 loci: dhfr N51I,
C59R, and S108N, as well as dhps A437G. All other sites were
pure wild type. Allele frequency for mutant alleles is shown in
Table 3. Of note, sulfadoxine-pyrimethamine (Fansidar) was
used as first-line treatment for uncomplicated malaria from
1993 to 2007, replacing chloroquine. Artemether-lumefantrine
was officially adopted as first-line treatment in 2007 [20].
DISCUSSION
During peak malaria season, daily CPT given to HEU infants
was associated with an overall reduction in the risk of malaria
infection between 6 and 36 weeks of life. This adds to our
previous findings that CPT is associated with reduced risk of
severe clinical malaria year round, and reduced nonsevere clinical
malaria in the first 10 weeks of life [5, 21]. However, we now pro-
vide the first evaluation of the impact of CPT on incidence and
characteristics of asymptomatic infections among HEU infants.
CPT remained effective at preventing asymptomatic infection
even in the setting of very high sulfadoxine-pyrimethamine resis-
tance. Reduction in malaria incidence occurred without signifi-
cant changes in parasitemia levels, the complexity of infections,
or the prevalence of drug resistance mutations.
Protection from asymptomatic parasitemia is important for
several reasons. First, asymptomatic infections frequently be-
come symptomatic [22, 23]. Second, it is likely that asymptom-
atic infections are not truly asymptomatic. There is concern that
even asymptomatic infections may have measurable adverse
clinical effects, in particular, hematologic abnormalities
among children and pregnant women [24–27]. Last, concerns
remain regarding the impact of asymptomatic infection on
transmission. Transmission may occur from asymptomatic pa-
tients and patients with submicroscopic parasitemia [28, 29]. In
feeding studies aimed at demonstrating the contribution of
asymptomatic infections to transmission, 1.2% of mosquitoes
feeding on asymptomatic persons vs 22% of mosquitoes feeding
on symptomatic persons developed oocysts in their guts [30].
Therefore, reduction in asymptomatic infection is likely to
have both individual clinical and public health benefits.
We previously evaluated the impact of CPT on malaria inci-
dence in BAN without restricting the year or season of the clin-
ical event, and found an overall protective effect of CPT on time
to incident clinical malaria [5]. However, the protective benefits
waned with infant age, similar to our current findings using
peak season clinical malaria events. Additionally, CPT was
found to be protective against severe clinical malaria (category
3 or 4 serious adverse event) and other severe infant morbidity
and mortality outcomes in this study population, with no di-
minished effect as infants aged [21].
Exposure status was based on time period, with a random re-
view of patient pharmacy records showing good adherence to
CPT guidelines [5]. However, as in all studies some exposure
misclassification is likely. In addition, we did not account for
loss to follow-up and instead used methods that allowed for re-
current malaria events. However, we found a similar association
between CPT and clinical malaria as previous BAN analyses
that accounted for potentially different follow-up times by
CPT exposure status.
Changes in national antimalarial policy increased the use of
more effective artemisinin combination therapies for treatment
of uncomplicated malaria during the study period. Increase in
effective therapy in the community could potentially affect the
risk of infection in the later time period (CPT exposed). How-
ever, our proxy for transmission (maternal malaria prevalence)
Table 3. Frequency of Antifolate Resistance Mutations in Infants
Unexposed or Exposed to Cotrimoxazole Preventive Therapy
Resistance
Mutation Replicate 1 Replicate 2 Mean SD P Valuea
dhfr N51I
CPT unexposed 98.6 97.4 98.0 0.8 .1
CPT exposed 99.5 99.4 99.5 0.1
dhfr C59R
CPT unexposed 96.6 96.5 96.6 0.1 .6
CPT exposed 96.0 96.7 96.4 0.5
dhfr S108N
CPT unexposed 99.7 99.6 99.7 0.1 .04
CPT exposed 99.9 99.9 99.9 0.0
No. of reads
dhfr 35 211 22 573 28 892 8936
dhps 17 885 20 400 19 143 1778
Abbreviations: CPT, cotrimoxazole preventive therapy; dhfr, dihydrofolate
reductase; dhps, dihydropteroate synthetase; SD, standard deviation.
a P value based on an unpaired t test.
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did not indicate a significant or meaningful change in malaria
prevalence between the 2 time periods. Last, the limited number
of available blood specimens may have biased our sample if
infants with and without an available specimen differed by
unmeasured variables, such as use of insecticide-treated bed
nets. However, infants with and without an available specimen
did not differ by any measured baseline covariates in BAN, sug-
gesting that these unmeasured variables are unlikely to have had
a significant impact.
Our findings add to the literature detailing the malaria-related
benefits of daily CPT use among HEU infants. As WHO guide-
lines now recommend administration of CPT to all HIV-exposed
infants, it would be unethical to conduct a randomized controlled
trial of CPT. Thus, retrospective observational studies such as this
one are key to evaluating the impact of WHO CPT recommen-
dations. Our findings support the claim that CPT reduces malaria
in HEU infants. However, we add important new insights into
the impacts of CPT on asymptomatic infection in a setting of
high antifolate resistance. As millions of HEU infants are poten-
tially given CPT amid high antifolate resistance, the reductions in
asymptomatic parasitemias may reduce malaria transmission and
be beneficial for malaria control.
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